HER2 in breast cancer is a significant therapeutic target, and the development of the nelipepimut-S peptide vaccine for HER2-positive patients has shown the potential to induce immune responses in clinical trials and may prevent recurrence [87]. This evidence concerns the gene ERBB2 and breast carcinoma.